Menu
Search
|

Menu

Close
X

Catalyst Pharmaceuticals Inc CPRX.OQ (NASDAQ Stock Exchange Capital Market)

3.43 USD
-- (--)
As of Feb 16
chart
Previous Close 3.43
Open --
Volume --
3m Avg Volume 227,555
Today’s High --
Today’s Low --
52 Week High 4.51
52 Week Low 1.08
Shares Outstanding (mil) 84.55
Market Capitalization (mil) 234.22
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-0.155
FY16
-0.218
FY15
-0.251
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
6.89
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-42.00
14.43
Return on Equity (TTM)
vs sector
-42.26
16.13

EXECUTIVE LEADERSHIP

Patrick McEnany
Chairman of the Board, President, Chief Executive Officer, Since 2006
Salary: $425,000.00
Bonus: $85,000.00
Alicia Grande
Chief Financial Officer, Vice President, Treasurer, Since 2011
Salary: $240,000.00
Bonus: $48,000.00
Steven Miller
Chief Operating Officer, Chief Scientific Officer, Since 2011
Salary: $300,000.00
Bonus: $100,000.00
David Muth
Executive Vice President, Chief Commercial Officer, Since 2015
Salary: --
Bonus: --
M. Douglas Winship
Vice President - Regulatory Operations, Since 2006
Salary: $198,414.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

355 Alhambra Cir Ste 1250
CORAL GABLES   FL   33134-5038

Phone: +1305.5292522

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.

SPONSORED STORIES